The global Animal Model Market is expanding as pharmaceutical and biotechnology companies increase investments in preclinical drug discovery, biomedical research, disease modeling, toxicology testing, vaccine development, and precision medicine. Animal models play an important role in evaluating therapeutic efficacy and safety before clinical studies. Increasing adoption of genetically engineered models, humanized mice, patient-derived xenografts, and disease-specific models is improving the ability of researchers to investigate complex diseases and develop targeted therapies.

According to Fortune Business Insights, the global animal model market was valued at USD 2.69 billion in 2025 and is projected to grow from USD 2.93 billion in 2026 to USD 5.87 billion by 2034, exhibiting a CAGR of 9.07% during the forecast period.

Why is the Animal Model Market Growing?

The increasing demand for preclinical testing and biomedical research is one of the major factors supporting market growth. Pharmaceutical and biotechnology companies use animal models to evaluate drug candidates, investigate disease mechanisms, assess toxicity, and study therapeutic responses before progressing to human trials.

Animal models are increasingly used for:

• Cancer research
• Infectious disease research
• Immunology
• Neurological disorders
• Metabolic diseases
• Toxicology studies
• Vaccine development
• Gene-editing research
• Drug discovery
• Precision medicine
• Antibody development
• Regenerative medicine

Fortune Business Insights reports that more than 62% of global drug-discovery studies involve animal testing during early-stage therapeutic evaluation, while the U.S. market benefits from extensive pharmaceutical R&D infrastructure and government-backed biomedical research programs.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Genetically Engineered Models